SpaceFund, based in Houston and Austin, has almost reached halfway for its $20 million fundraise. Photo via NASA/Unsplash

A venture capital firm co-located in Houston and Austin has announced a recent closing of a $20 million fund.

SpaceFund has raised $9 million toward its its $20 million BlastOff Fund as of this week — surpassing its initial first close goal of $5 million.

"We are thrilled to see how many investors are placing their trust in our team," says SpaceFund founder Rick Tumlinson in a news release. "We spent a lot of time slowly and carefully developing our processes and credibility, so we can better serve both investors and the amazing space startup community, and it's paying off."

Launched in 2019 with an initial fund that closed in August of 2020, SpaceFund has already invested in 13 exciting space startups. The new fund will build on those investments while also expanding its portfolio, according to the release.

"SpaceFund is about combining a bold approach with a very conservative diligence and investment process," says Meagan Crawford, SpaceFund's managing partner, in the release. "The BlastOff Fund continues our careful growth plan but is designed to accelerate our ability to place investment into those companies that are leading the Space Revolution."

San Francisco-based innovator Jed McCaleb — co-founder and the CTO of Stellar Development Foundation, a nonprofit building an accessible cryptocurrency platform — anchored the BlastOff Fund.

"I came to SpaceFund to ask questions because they are seen as credible thought leaders in the space investment industry," McCaleb says in the release. "By the time we finished talking, it was clear they were an obvious choice to help me invest in this amazing field."

McCaleb has a keen interest in commercial space, according to the release.

"Jed is a well-informed investor and one who deeply cares about the future of space and humanity," adds Crawford. "He is exactly the kind of investor we hope to attract into the SpaceFund family. For us, this isn't just about money. It is about how we can best impact the future. Jed and the other investors in the fund get that."

Houston-based space companies Axiom Space, Eden Grow Systems, and Cognitive Space are among SpaceFund's current portfolio.

"There is a reason we call this the BlastOff fund," says Tumlinson. "Anyone who follows what is happening in space can see that after almost 60 years, this industry is taking off. Our job is to help investors climb aboard the right companies to carry them to their financial destinations as we open the Frontier."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.